NR0B1 and breast carcinoma: Estrogen receptor alpha (ERα) is a nuclear hormone receptor and a key driver of tumorigenesis and tumor progression in these breast cancers, and it is a key treatment target and a biomarker predictive of response to endocrine therapy [46].